The stock's near-term catalyst path is binary: relutrigine PDUFA on Dec 27 and ulixacaltamide PDUFA on Jan 29. The EMERALD readout in Q4 adds another binary event. Monitor FDA advisory committee schedules and any pre-PDUFA briefing documents.
Drugs in focus
PRAX drug pipeline →relutrigine
▲ Bullish Named in this press release- Impact
- Phase
- Filed/PDUFA (NDA under priority review)
- Time to market
- PDUFA target action date is December 27, 2026. If approved, a U.S. launch could follow in early 2027.
- Next catalyst
- PDUFA date · Dec 27, 2026 41d
What to watchThe next binary catalyst is the PDUFA decision on December 27, 2026, roughly six weeks away. Approval would likely drive a significant re-rating given no approved therapies exist for SCN2A/SCN8A DEEs, while a CRL would pressure the stock. Also watch for EMERALD study topline results in broad DEEs (Q4 2026), which could expand the addressable market.
- ▲ ulixacaltamide 8/10 Filed/NDA under FDA review (PDUFA January 29, 2027) · PDUFA date Jan 29, 2027 Named in filing
- ● vormatrigine 5/10 Phase 3 Named in filing
- ◆ elsunersen 4/10 Phase 2/3 (registrational) Named in filing
- ● PRAX-050 Fresh report · subscribers
- ● PRAX-051 Fresh report · subscribers
- 3 more · All PRAX drugs, catalysts & trials →
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 9 $332.97entry
- T+1 · 7d ago +1.39%α +1.76% · $337.59
- T+5 · 16h ago −6.82%α −5.12% · $310.27
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Praxis Precision Medicines reported Q3 2026 net loss of $94.2M ($3.23 per share), wider than the $73.9M loss a year ago, with no revenue. The focus is on two upcoming PDUFA dates: relutrigine (Dec 27, 2026) and ulixacaltamide (Jan 29, 2027), plus an EMERALD readout in Q4 2026. Cash of $1.3B funds operations into 2028.
Key Financial Metrics
Key Facts
- Net loss of $94.2M for Q3 2026 vs $73.9M in Q3 2025
- GAAP EPS of ($3.23) vs consensus estimate of ($3.63), a beat
- Cash and investments of $1.3B as of Sep 30, 2026, up from $926.1M at Dec 31, 2025
- PDUFA target action date for relutrigine: Dec 27, 2026
- PDUFA target action date for ulixacaltamide: Jan 29, 2027
- EMERALD study topline results expected in Q4 2026
- R&D expenses $64.2M vs $65.8M year-over-year
- G&A expenses $42.7M vs $12.6M year-over-year, driven by commercial launch preparations
- 27.9M shares outstanding as of Sep 30, 2026
Financial Impact
Net loss widened by $20.3M YoY; cash burn rate increased with G&A spending up $30.1M for launch readiness
Risk Factors
- FDA non-approval or complete response letter for either NDA
- Negative or inconclusive EMERALD topline results
- Cash burn accelerating with commercial buildout before revenue generation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3398230 |
Track record
16 reports on PRAX
5 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +15.73% at T+60 after the Jun 29, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $317.69 Now $310.27 +2.34% settles Feb 12
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $328.13 Now $310.27 −5.44% settles Feb 11
- Nov 9, 20267d ago Press Release Neutral 4/10 Viewing Entry $332.97 Now $310.27 −6.82% settles Feb 5
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $262.59 Now $310.27 +18.16% settles Feb 3
- Nov 4, 202612d ago Press Release Neutral 1/10 Entry $262.59 Now $310.27 +18.16% settles Feb 3
- Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $288.62 Now $310.27 +7.50% settles Jan 27
- Jun 29, 202620w ago 8-K Bearish 6/10 Entry $334.79 to $282.12 Now $310.27 +7.32% ▲ +15.73% +18.55% vs SPY
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $247.98 to $351.81 Now $310.27 +25.12% ▲ +41.87% +37.47% vs SPY
- Jun 2, 202623w ago Press Release Neutral 1/10 Entry $278.93 to $367.85 Now $310.27 +11.24% ▲ +31.88% +29.38% vs SPY
- May 7, 202627w ago Press Release Bullish 8/10 Entry $333.28 to $305.51 Now $310.27 −6.90% ▼ −8.33% −12.17% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers